CeQur Simplicity SA news
CeQur®, a medical device company committed to simplifying the lives of people with diabetes by revolutionizing insulin-delivery solutions, today announced the appointments of Rick Doubleday and Meret Gaugler, Ph.D., to its Board of Directors.
Progression of Type 2 Diabetes Treatment
- Due to natural progression of type 2 diabetes, maintenance of glycemic targets requires a stepwise approach to treatment in order to achieve and maintain glycemic control and avoid complications1`2
- Comprehensive lifestyle modifications combined with metformin
- Addition of up to 3 oral medications or GLP-1 RA injection
- Addition of basal (long-acting) insulin
- Addition of mealtim
ATTENTION:
CeQur announced that the company has appointed Bradley Paddock as chief executive officer, effective today. Paddock brings a track record of commercial medtech successes, notably leading sales up to $600 million during his eight-year tenure at Kyphon, Inc. Paddock also managed successful commercial operations for multiple industry-leading companies, including Stryker, Bausch + Lomb, Inc., and Medtronic, Inc.
CeQur® announced the appointment of Peter B. Luther to its board of directors, effective immediately. Luther is a 29-year veteran of the medical device and diagnostics, OTC drugs and consumer-packaged goods industries.
ATTENTION: You will be leaving CeQur’s website. CeQur does not control the content of the website you are visiting
CeQur today announced that the company has acquired select assets of Calibra Medical, Inc., one of the Johnson & Johnson Diabetes Care Companies. The transaction includes an exclusive worldwide license for the wearable, on-demand insulin delivery system previously known as OneTouch Via™. The Calibra system enables people with diabetes to discreetly and conveniently deliver rapid-acting insulin at mealtime.